肾盂肾炎 中国就医指南

Pyelonephritis is a bacterial infection of the renal pelvis and parenchyma, representing an upper urinary tract infection that can range from acute, self-limiting inflammation to severe, life-threatening complications such as sepsis or renal abscess. It typically arises via ascending infection—most commonly from Escherichia coli (70–90% of cases)—which migrates from the bladder through the ureters to the kidneys. Less frequently, it occurs hematogenously, especially in immunocompromised individuals or those with bacteremia. Pathogenesis involves bacterial adherence to uroepithelial cells via fimbriae (e.g., type 1 and P fimbriae), invasion into tubular epithelium, biofilm formation, and activation of innate immune responses leading to neutrophil infiltration, interstitial edema, and microabscesses. Chronic pyelonephritis—often associated with vesicoureteral reflux, obstructive uropathy, or recurrent infections—may result in progressive scarring, atrophy, and irreversible loss of nephron function, potentially contributing to hypertension and chronic kidney disease.

Epidemiologically, acute pyelonephritis affects approximately 10–15 per 10,000 adults annually in high-income countries, with a marked female predominance (female-to-male ratio ~3:1) due to shorter urethral anatomy and hormonal influences. Incidence peaks in women aged 18–39 years and again in older adults (>65 years), particularly among those with comorbidities. In China, community-acquired pyelonephritis accounts for ~2–4% of all adult hospital admissions for infectious diseases, with rising rates linked to antimicrobial resistance and aging populations. Risk factors include urinary tract obstruction (e.g., stones, strictures, benign prostatic hyperplasia), neurogenic bladder, diabetes mellitus, pregnancy, recent urinary instrumentation (catheterization, cystoscopy), immunosuppression, and structural abnormalities (e.g., horseshoe kidney, reflux). Notably, multidrug-resistant (MDR) Enterobacterales—including extended-spectrum beta-lactamase (ESBL)-producing strains—are increasingly reported in Chinese tertiary centers, complicating empiric therapy.

Quality of life impact is substantial. Acute episodes cause debilitating symptoms—fever, flank pain, nausea, vomiting, dysuria, and urgency—that often impair daily functioning, work productivity, and sleep continuity. Recurrent or chronic disease correlates with anxiety, depression, sexual dysfunction (especially in women with persistent lower UTI symptoms), and reduced physical health scores on validated scales (e.g., SF-36). Long-term sequelae—including hypertension, proteinuria, and accelerated eGFR decline—further erode health-related quality of life, particularly in patients with preexisting CKD or metabolic syndrome. Early diagnosis, pathogen-directed therapy, and comprehensive risk-factor mitigation are therefore essential not only for clinical resolution but also for preserving renal reserve and psychosocial well-being.

# 肾盂肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：急性单纯性肾盂肾炎、轻中度感染、无尿路梗阻及肾功能正常者。

• •药物治疗（7–14日）：

- 静脉抗生素（头孢曲松/哌拉西林他唑巴坦）：药费+输液费 1,800–4,200元；

• •检验检查费：尿常规+培养+药敏、血常规、CRP、肾功能、泌尿系超声：320–680元；
• •理疗/支持治疗（可选）：中药灌肠、穴位贴敷等辅助疗法：200–500元/疗程。

二、手术/介入治疗方案

适用人群：合并尿路梗阻（如结石、狭窄）、脓肿形成、反复复发或引流失败者。

• •经皮肾造瘘术（PCN）：解除梗阻、引流脓液，含术前CT/超声引导、术后护理：8,500–14,000元；
• •输尿管镜碎石+支架置入：针对结石继发感染，含麻醉、耗材、住院：16,000–28,000元；
• •术前必查：增强CT尿路成像（CTU）、心电图、凝血功能、感染四项：1,200–2,100元。

三、复杂/耐药/并发症方案

• •多重耐药菌（如ESBLs、CRE）：碳青霉烯类静脉治疗+药敏监测，疗程延长至21天：药费 12,000–35,000元；
• •肾周脓肿/坏死性肾盂肾炎：需多学科协作，ICU监护+外科清创：总费用 45,000–98,000元。

四、方案快速选择指南

• •预算≤5,000元/轻症：首选门诊口服抗生素+基础检查；
• •预算8,000–25,000元/梗阻性感染：推荐PCN或输尿管镜微创引流；
• •耐药/重症/脓肿：直接收治肾内科联合泌尿外科，启动多学科诊疗（MDT）路径。